NCT00066872CompletedPhase 3
A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma
Queen's Medical Center6 sites in 1 country500 target enrollmentStarted: October 1, 2002Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 500
- Locations
- 6
- Primary Endpoint
- Absence of local recurrence at 3 years after start of treatment
Study Overview
Brief Summary
RATIONALE: Biological therapies such as imiquimod use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known if topical imiquimod is more effective than surgery in treating basal cell skin cancer.
PURPOSE: This randomized phase III trial is studying how well topical imiquimod works compared to surgery in treating patients with basal cell skin cancer.
Detailed Description
OBJECTIVES:
- Compare the rate of local recurrence at 3 years in patients with nodular or superficial basal cell skin cancer treated with imiquimod 5% cream vs excisional surgery.
- Compare recurrence at 6 months and 1, 2, and 5 years in patients treated with these regimens.
- Compare the time to first recurrence in patients treated with these regimens.
- Compare the aesthetic appearance of lesion sites in patients treated with these regimens.
- Compare pain in patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center and lesion type (nodular vs superficial). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive topical imiquimod to a single lesion once daily for 6 weeks for a superficial lesion or 12 weeks for a nodular lesion. Patients with early treatment failure or recurrence are offered surgical excision.
- Arm II: Patients undergo surgical excision. Patients are followed at 6, 12, and 18 weeks, every 6 months for 1 year, annually for 2 years, and then at 5 years.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Primary Purpose
- Treatment
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed primary basal cell skin carcinoma
- •Nodular or superficial lesion(s)*
- •Located in low-risk areas NOTE: *Any number of lesions are allowed but only 1 lesion per patient is selected for the study
- •No genetic or nevoid conditions (e.g., Gorlin's syndrome)
- •No morphoeic (microinfiltrative) histology
- •PATIENT CHARACTERISTICS:
- •Performance status
- •Not specified
- •Life expectancy
- •Not specified
- •Hematopoietic
- •No bleeding disorder
- •Not specified
- •Not specified
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for up to 1 month after study participation
- •No allergy to any of the study interventions
- •No life-threatening disease
- •Must be available for study follow-up for up to 3 years
- •Must have access to a telephone
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •Not specified
- •Chemotherapy
- •Not specified
- •Endocrine therapy
- •Not specified
- •Radiotherapy
- •Not specified
- •Not specified
- •No concurrent participation in any other experimental trial
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Absence of local recurrence at 3 years after start of treatment
Secondary Outcomes
- Recurrence of basal cell cancer (BCC) at 1, 2, and 5 years
- Aesthetic appearance of lesion site as measured by participant and blind observer using 5-point Likert scale at 6 months, and then years 1-3
- Time to first occurrence up to 5 years from completion of study treatment
- Pain at lesion site as measured by 6-point scale daily during treatment, and then 16 weeks after the completion of study treatment
- Cost effectiveness assessed up to 3 or 5 years
Investigators
Study Sites (6)
Loading locations...
Similar Trials
Completed
Not Applicable
Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the VulvaVulvar CancerNCT00504023Memorial Sloan Kettering Cancer Center8
Completed
Phase 1
Imiquimod Cream in Treating Patients With Basal Cell Skin CancerNon-melanomatous Skin CancerNCT00079300National Naval Medical Center
Completed
Phase 1
Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the SkinMelanoma (Skin)Metastatic CancerNCT00453050University of Oklahoma11
Terminated
Phase 2
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin LymphomaLymphomaNCT00848328University of California, Davis30
Withdrawn
Phase 2
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by SurgeryBrain and Central Nervous System TumorsNCT00814593Lisata Therapeutics, Inc.